Accelerometer measured physical activity and the incidence of cardiovascular disease: Evidence from the UK Biobank cohort study.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
07
05
2020
accepted:
26
11
2020
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
7
5
2021
Statut:
epublish
Résumé
Higher levels of physical activity (PA) are associated with a lower risk of cardiovascular disease (CVD). However, uncertainty exists on whether the inverse relationship between PA and incidence of CVD is greater at the highest levels of PA. Past studies have mostly relied on self-reported evidence from questionnaire-based PA, which is crude and cannot capture all PA undertaken. We investigated the association between accelerometer-measured moderate, vigorous, and total PA and incident CVD. We obtained accelerometer-measured moderate-intensity and vigorous-intensity physical activities and total volume of PA, over a 7-day period in 2013-2015, for 90,211 participants without prior or concurrent CVD in the UK Biobank cohort. Participants in the lowest category of total PA smoked more, had higher body mass index and C-reactive protein, and were diagnosed with hypertension. PA was associated with 3,617 incident CVD cases during 440,004 person-years of follow-up (median (interquartile range [IQR]): 5.2 (1.2) years) using Cox regression models. We found a linear dose-response relationship for PA, whether measured as moderate-intensity, vigorous-intensity, or as total volume, with risk of incident of CVD. Hazard ratios (HRs) and 95% confidence intervals for increasing quarters of the PA distribution relative to the lowest fourth were for moderate-intensity PA: 0.71 (0.65, 0.77), 0.59 (0.54, 0.65), and 0.46 (0.41, 0.51); for vigorous-intensity PA: 0.70 (0.64, 0.77), 0.54 (0.49,0.59), and 0.41 (0.37,0.46); and for total volume of PA: 0.73 (0.67, 0.79), 0.63 (0.57, 0.69), and 0.47 (0.43, 0.52). We took account of potential confounders but unmeasured confounding remains a possibility, and while removal of early deaths did not affect the estimated HRs, we cannot completely dismiss the likelihood that reverse causality has contributed to the findings. Another possible limitation of this work is the quantification of PA intensity-levels based on methods validated in relatively small studies. In this study, we found no evidence of a threshold for the inverse association between objectively measured moderate, vigorous, and total PA with CVD. Our findings suggest that PA is not only associated with lower risk for of CVD, but the greatest benefit is seen for those who are active at the highest level.
Sections du résumé
BACKGROUND
Higher levels of physical activity (PA) are associated with a lower risk of cardiovascular disease (CVD). However, uncertainty exists on whether the inverse relationship between PA and incidence of CVD is greater at the highest levels of PA. Past studies have mostly relied on self-reported evidence from questionnaire-based PA, which is crude and cannot capture all PA undertaken. We investigated the association between accelerometer-measured moderate, vigorous, and total PA and incident CVD.
METHODS AND FINDINGS
We obtained accelerometer-measured moderate-intensity and vigorous-intensity physical activities and total volume of PA, over a 7-day period in 2013-2015, for 90,211 participants without prior or concurrent CVD in the UK Biobank cohort. Participants in the lowest category of total PA smoked more, had higher body mass index and C-reactive protein, and were diagnosed with hypertension. PA was associated with 3,617 incident CVD cases during 440,004 person-years of follow-up (median (interquartile range [IQR]): 5.2 (1.2) years) using Cox regression models. We found a linear dose-response relationship for PA, whether measured as moderate-intensity, vigorous-intensity, or as total volume, with risk of incident of CVD. Hazard ratios (HRs) and 95% confidence intervals for increasing quarters of the PA distribution relative to the lowest fourth were for moderate-intensity PA: 0.71 (0.65, 0.77), 0.59 (0.54, 0.65), and 0.46 (0.41, 0.51); for vigorous-intensity PA: 0.70 (0.64, 0.77), 0.54 (0.49,0.59), and 0.41 (0.37,0.46); and for total volume of PA: 0.73 (0.67, 0.79), 0.63 (0.57, 0.69), and 0.47 (0.43, 0.52). We took account of potential confounders but unmeasured confounding remains a possibility, and while removal of early deaths did not affect the estimated HRs, we cannot completely dismiss the likelihood that reverse causality has contributed to the findings. Another possible limitation of this work is the quantification of PA intensity-levels based on methods validated in relatively small studies.
CONCLUSIONS
In this study, we found no evidence of a threshold for the inverse association between objectively measured moderate, vigorous, and total PA with CVD. Our findings suggest that PA is not only associated with lower risk for of CVD, but the greatest benefit is seen for those who are active at the highest level.
Identifiants
pubmed: 33434193
doi: 10.1371/journal.pmed.1003487
pii: PMEDICINE-D-20-01924
pmc: PMC7802951
doi:
Substances chimiques
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003487Subventions
Organisme : Medical Research Council
ID : G0902393
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S502509/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M501633/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K006584/1
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-0407-10314
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : British Heart Foundation
ID : SP/18/4/33803
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : Department of Health
ID : 05/40/04
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_13041
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
I have read the journal's policy and the authors of this manuscript have the following competing interests: KR has in the past received personal fees as Associate Editor for PLOS Medicine and as Associate Editor, is in receipt of Personal Fees from BMJ Heart. MW is a consultant to Amen and Kirin. RW is supported by a Medical Research Council Industrial Strategy Studentship (grant number MR/S502509/1). The Medical Research Council had no role in the study design; collection, analysis, and interpretation of data; writing of the paper; and/or decision to submit for publication.
Références
Am J Kidney Dis. 2007 Jan;49(1):3-7
pubmed: 17185140
Nat Commun. 2018 Dec 10;9(1):5257
pubmed: 30531941
Med Sci Sports Exerc. 2008 Jan;40(1):181-8
pubmed: 18091006
BMJ. 2019 Aug 21;366:l4570
pubmed: 31434697
PLoS One. 2015 Dec 29;10(12):e0145950
pubmed: 26713857
PLoS One. 2015 Nov 04;10(11):e0141274
pubmed: 26536618
BMJ. 2019 Apr 17;365:l1495
pubmed: 30995986
Int J Obes (Lond). 2019 Nov;43(11):2333-2342
pubmed: 30940917
Prev Med. 2016 Oct;91:389-394
pubmed: 27330025
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Circulation. 2010 Aug 17;122(7):743-52
pubmed: 20713909
Int J Epidemiol. 2019 Aug 1;48(4):1381
pubmed: 31373623
BMJ. 2020 Feb 12;368:m131
pubmed: 32051121
Med Sci Sports Exerc. 2018 Feb;50(2):257-265
pubmed: 28976493
Eur J Epidemiol. 2014 Nov;29(11):851-7
pubmed: 25354993
BMJ Open. 2019 Jan 29;9(1):e024206
pubmed: 30700478
Circulation. 2015 Feb 24;131(8):721-9
pubmed: 25688148
Med Sci Sports Exerc. 2020 Apr;52(4):876-883
pubmed: 31688655
Int J Epidemiol. 2011 Feb;40(1):121-38
pubmed: 20630992
Br J Cancer. 2003 Aug 18;89(4):605-11
pubmed: 12915864
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034
pubmed: 28641372
Circulation. 2018 Jan 9;137(2):203-205
pubmed: 29109088
JAMA Cardiol. 2017 Dec 1;2(12):1349-1358
pubmed: 29117341
JAMA. 2018 Nov 20;320(19):2020-2028
pubmed: 30418471
JAMA Intern Med. 2015 Jun;175(6):959-67
pubmed: 25844730
Med Sci Sports Exerc. 2015 Apr;47(4):833-8
pubmed: 25102292
Circulation. 2011 Aug 16;124(7):789-95
pubmed: 21810663
Med Sci Sports Exerc. 2014 Sep;46(9):1816-24
pubmed: 24887173
PLoS One. 2017 Feb 1;12(2):e0169649
pubmed: 28146576
Int J Cardiol. 2019 Mar 1;278:267-272
pubmed: 30578094
Br J Sports Med. 2003 Jun;37(3):197-206; discussion 206
pubmed: 12782543